20:41 , Jan 18, 2019 |  BC Week In Review  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
23:21 , Jan 17, 2019 |  BC Extra  |  Company News

Boehringer taps BioMed X to source psychiatric disease research proposals

Boehringer Ingelheim GmbH (Ingelheim, Germany) expanded its collaboration with public-private accelerator BioMed X GmbH (Heidelberg, Germany) to explore novel disease mechanisms in schizophrenia and other psychiatric diseases, which Boehringer said is one of its key...
16:55 , Mar 16, 2018 |  BC Week In Review  |  Company News

BioMed X, Roche parter to treat immune-mediated diseases

BioMed X GmbH (Heidelberg, Germany) and Roche (SIX:ROG; OTCQX:RHHBY) partnered to develop treatments for undisclosed immune-mediated diseases. BioMed X will launch a global call for applications to establish a new biomedical research group. Final winners...
22:02 , Dec 1, 2017 |  BC Week In Review  |  Company News

BioMed X, J&J in research deal

BioMed X GmbH (Heidelberg, Germany) and the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) partnered to house up to five Janssen research projects at the BioMed X Innovation Center. The first...
19:43 , Nov 11, 2016 |  BC Week In Review  |  Company News

Merck KGaA, BioMed X deal

BioMed X and Merck created a research group to develop methods to increase efficacy and reduce side effects of radiation and radiochemotherapy used to treat cancer. The research aims to exploit cellular DNA damage and...
07:00 , Jul 14, 2016 |  BC Innovations  |  Strategy

Borderless at Boehringer

With the launch of its new Innovation Unit on July 1, Boehringer Ingelheim GmbH is not only reorganizing its various research teams to streamline R&D, but is ramping up external partnerships to explore new biological...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Company News

BioMed X, Boehringer Ingelheim deal

The companies added a new team of scientists to “discover novel therapeutic concepts” for psychiatric diseases to a 2015 deal covering chronic obstructive pulmonary disease (COPD). BioMed X will be responsible for recruitment and operations....